The FDA approved Biogen and Ionis Pharmaceuticals' nusinersen for spinal muscular atrophy (SMA) in December 2016.
SMA is a hereditary muscle-wasting disease caused by loss-of-function mutations in the survival motor neuron 1 (SMN1) gene. Nusinersen is an antisense oligonucleotide that modulates the splicing of the related SMN2 gene. By increasing the inclusion of exon 7 into SMN2 mRNA, the drug drives production of a compensatory protein.
Interim results from a phase III trial of 121 patients showed that 40% of nusinersen-treated patients made motor milestone improvements, compared with 0% in the control patients. Data released after the approval show that the drug also reduces the risk of death or permanent ventilation: 39% of nusinersen-treated patients died or required permanent ventilation during the study, versus 68% of control patients.
The landmark drug carries a landmark cost: US$750,000 for the first year and $375,000 per year thereafter.
The FDA has approved one other splice-modulating drug, Sarepta's eteplirsen for Duchenne muscular dystrophy. This was a controversial approval that was based on data from an inconclusive 12-patient study.
Splice-modulating drugs could have utility in various other indications (Nat. Rev. Drug Discov., published online 22 July 2016).
Rights and permissions
About this article
Cite this article
Mullard, A. FDA approves splice-modulating drug. Nat Rev Drug Discov 16, 77 (2017). https://doi.org/10.1038/nrd.2017.18
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.18
This article is cited by
-
Why Do We Care More About Disease than Health?
Phenomics (2022)